Case number# PHHY2015RO086213, is an initial literature case report received on 17 Jul 2015. This report refers 
to a 49-year-old male patient. The patient who was diagnosed with multiple sclerosis with history of treatment with 
INF-beta for 10 months until Sep 2010 
Patient received Gilenya 0.5mg (fingolimod) once daily orally from Oct 2010. 
In Oct 2014, his lymphocyte count was 0.59-0.89x10^9/l. On the date of 09 Dec 2014, the lymphocytes account 
dropped to 0.24 x 10^9/L. On 23 Jan 2015 the patient had an MRI with characteristic lesions for progressive 
multifocal leucoencephalopathy (PML). 
On 26 Jan 2015, the patient discontinued the treatment with Gilenya. The diagnostic of PML was confirmed through
PCR done from cerebrospinal fluid. The patient did not present any signs or symptoms associated with the 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 212 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
diagnostic of PML. On 09 Feb 2015, the lymphocytes account was 0.64x10^9/L. 
Outcome of the event was reported as recovered. Seriousness of the event progressive multifocal 
leucoencephalopathy was reported as medically significant. Author assessed that the event was suspected to be 
related to Gilenya.
Author reported that this was the first case of PML reported to a patient with multiple sclerosis who did not have 
previously treatment with natalizumab.
Following an internal review done on 29 May 2015, the case PRO2015RO089179 was identified as duplicate of the 
case PHHY2015DE0149. Hence the information of the case PRO2015RO089179 will be merged into the case 
PHHY2015DE0149 and the case PRO2015RO089179 will be deactivated